Author:
Zhang Chu,Kong Feng-Wei,Wu Wen-Bin,Zhang Miao,Yu Guang-Mao,Wang Xiang,Liu Yuan-Yuan
Funder
Zhejiang Medical and Health Research Fund Project
Agencia Nacional de Promoción Científica y Tecnológica
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference35 articles.
1. Anlotinib: first global approval;Syed;Drugs,2018
2. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy;Zhou;Cancer Commun (Lond),2019
3. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors;Sun;J Hematol Oncol,2016
4. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development;Shen;J Hematol Oncol,2018
5. NCCN guidelines insights: non-small cell lung cancer, version 1.2020;Ettinger;J Natl Compr Canc Netw,2019
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献